diaDexus, Inc. – ‘8-K’ for 10/23/03

On:  Friday, 10/24/03, at 2:42pm ET   ·   For:  10/23/03   ·   Accession #:  1169232-3-6168   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3      9K 
 2: EX-99.1     Press Release                                          2     10K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

----------

FORM 8-K

CURRENT REPORT

 Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2003

VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)

     DELAWARE                        0-26483                94-3236309
(State or other jurisdiction of  (Commission File Number)    (I.R.S. Employer   
incorporation or organization)                            Identification Number)

 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
 (Address of Principal Administrative Offices)

 Registrants Telephone Number, Including Area Code: (650) 624-1000

8-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Item 5. Other Events and Regulation FD Disclosure.                              

      On October 23, 2003, VaxGen, Inc. issued a press release entitled, "VaxGen
Reviewing Accounting Treatment for Warrants Associated with 2001 Financing and  
May Restate Certain Financial Statements; No Impact on Cash Position Expected". 

This press release is attached as Exhibit 99.1 to this report and is
incorporated herein by reference.                                               

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.     

(c)   Exhibits.                                                     

Exhibit No.       Description                                                   
-----------       -----------                                                   

99.1              Press release dated October 23, 2003, entitled, "VaxGen       
               Reviewing Accounting Treatment for Warrants Associated with
                2001 Financing and May Restate Certain Financial Statements;
No Impact on Cash Position Expected".       

8-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the        
registrant has duly caused this report to be signed on its behalf by the        
undersigned hereunto duly authorized.                                           

                                            VaxGen, Inc.
                                            (Registrant)

Dated: October 24, 2003                    By: /s/ Carter A. Lee                
                                            ------------------------------
                        Carter Lee
                                   Senior Vice President
                                      Finance & Administration

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on:		10/24/03		3					None on these Dates
For Period End:		10/23/03		1		2
									List all Filings